Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

treated with interferon and ribavirin alone, although conclusions regarding safety cannot be made until results in more patients over longer duration are known.  Positive preliminary SVR data were also presented.
  • AASLD 2010, IL28B Poster data showed that the addition of ANA598 to SOC has the potential to confer beneficial effect on HCV patients regardless of IL-28B genotype.
  • EASL 2010 and ICAR 2010, Preclinical Posters – presented data showing enhanced antiviral activity and suppression of resistance when ANA598 is combined in vitro with other anti-HCV agents that act through diverse mechanisms, including protease inhibition, polymerase inhibition (both nucleoside and non-nucleoside inhibitors) and cyclophilin inhibition (a host target).

  • Conference Call WebcastAnadys will host a conference call at 5:00 pm Eastern Standard Time today to discuss its fourth quarter and year-end 2010 financial results and highlights.  A live webcast of the call, including accompanying slides, will be available online at www.anadyspharma.com.  A telephone replay will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 62030425.  The webcast and telephone replay will be available through March 17, 2011.Condensed Consolidated Financial StatementsAnadys Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations(In thousands except per share amounts)(Unaudited)Three Months EndedDecember 31,Twelve Months EndedDecember 31,2010200920102009Operating expensesResearch and development

    $

    2,753$

    3,948$

    12,026$

    19,494General and administrative1,7271,6326,4788,243Total operating expenses (1)4,4805,58018,50427,737Interest income and other, net2544139610Gain (loss) from valuation of common sto
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
    (Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
    (Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
    (Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
    Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
    ... YORK, Feb. 23 NeoStem, Inc. (NYSE Alternext ... processing and long-term storage of adult stem cells ... signed a license agreement to obtain the exclusive ... applications for cosmetic facial and body procedures and ...
    ... Pa. and SHANGHAI, Feb. 23 Frontage Laboratories ... bioanalytical, pre-clinical, clinical and drug development services to ... has expanded its research and development agreement with ... Beijing Pharmaceutical Group ("Beijing Pharma"), to accelerate Beijing ...
    ... (Amex: ETC ) ("ETC" or the "Company") ... equipped to satisfy the requirements of Electronic Medical Records ... University on January 8, 2009, then President-Elect Barack ... care while lowering its costs, we will make the ...
    Cached Biology Technology:NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 2NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 3Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 2Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 3Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 4Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 2Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 3Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 4
    (Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading ... study that pinpoints fine-scale differences in genetic ancestry of ... . Since immigrants first arrived more than ... has served as a meeting place for ... history and the ongoing mixing of peoples with African, ...
    (Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
    (Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
    Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
    ... year the American Institute of Biological Sciences (AIBS) ... to the biological sciences. Since 1972, AIBS ... individuals who have made significant scientific contributions to ... integrative and organismal biology. The award is ...
    ... Barack Obama and Energy Secretary Steve Chu are consistent ... fuels, carbon-neutral biofuels as an alternative to gasoline are ... to biofuels has been on global warming, such a ... the Energy Biosciences Institute (EBI) has produced a novel ...
    ... Spanish . , In the context of the ... light on global warming are of great interest. That is ... of solid or liquid particles on a gaseous environment that ... Juan Luis Guerrero Rascado developed his doctoral ...
    Cached Biology News:Two Central High (Philadelphia) grads honored by AIBS 2The coming of biofuels: Study shows reducing gasoline emissions will benefit human health 2The coming of biofuels: Study shows reducing gasoline emissions will benefit human health 3The coming of biofuels: Study shows reducing gasoline emissions will benefit human health 4A research work will be the reference to characterize the climatic impact of desert dust 2
    GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
    Recombinant Rat Leptin, CF...
    actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
    ...
    Biology Products: